Advertisement
Australia markets closed
  • ALL ORDS

    7,999.20
    -83.90 (-1.04%)
     
  • ASX 200

    7,727.60
    -84.20 (-1.08%)
     
  • AUD/USD

    0.6631
    +0.0022 (+0.33%)
     
  • OIL

    77.80
    +0.93 (+1.21%)
     
  • GOLD

    2,335.20
    -2.00 (-0.09%)
     
  • Bitcoin AUD

    104,352.63
    +315.59 (+0.30%)
     
  • CMC Crypto 200

    1,450.52
    -17.58 (-1.20%)
     
  • AUD/EUR

    0.6109
    +0.0005 (+0.08%)
     
  • AUD/NZD

    1.0823
    -0.0005 (-0.04%)
     
  • NZX 50

    11,783.39
    -26.09 (-0.22%)
     
  • NASDAQ

    18,808.35
    +184.96 (+0.99%)
     
  • FTSE

    8,317.59
    -21.64 (-0.26%)
     
  • Dow Jones

    39,069.59
    +4.33 (+0.01%)
     
  • DAX

    18,693.37
    +2.05 (+0.01%)
     
  • Hang Seng

    18,608.94
    -259.77 (-1.38%)
     
  • NIKKEI 225

    38,646.11
    -457.11 (-1.17%)
     

Stratec Full Year 2023 Earnings: Misses Expectations

Stratec (ETR:SBS) Full Year 2023 Results

Key Financial Results

  • Revenue: €261.9m (down 4.6% from FY 2022).

  • Net income: €13.1m (down 55% from FY 2022).

  • Profit margin: 5.0% (down from 11% in FY 2022). The decrease in margin was primarily driven by lower revenue.

  • EPS: €1.08 (down from €2.41 in FY 2022).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Stratec Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 24%.

Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany.

ADVERTISEMENT

Performance of the German Medical Equipment industry.

The company's shares are down 5.7% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Stratec you should be aware of, and 1 of them is a bit unpleasant.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.